A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Clinical trial NCT05147662 · COMPLETED

Trial details

NCT number: NCT05147662
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Treatment of Bleeding Prophylaxis of Bleeding Hemophilia A Children

Start date: 2022-03-23
Primary completion: 2024-01-04
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.